Nilotinib as first-line therapy for chronic myeloid leukemia.
Indian J Cancer
;
2011 Oct-Dec; 48(4): 438-445
Artículo
en Inglés
| IMSEAR
| ID: sea-144524
ABSTRACT
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Piperazinas
/
Pirimidinas
/
Proteínas Tirosina Quinasas
/
Humanos
/
Resistencia a Medicamentos
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Supervivencia sin Enfermedad
/
Terapia Molecular Dirigida
/
Animales
/
Antineoplásicos
Idioma:
Inglés
Revista:
Indian J Cancer
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS